NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) released its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 analysts have issued 1 year target prices for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.44 in the next twelve months. This suggests a possible upside of 46.7% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Media coverage about KIN stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a decrease in short interest in December. As of December 13th, there was short interest totalling 671,100 shares, a decrease of 5.5% from the November 28th total of 709,900 shares. Based on an average daily trading volume, of 98,200 shares, the short-interest ratio is presently 6.8 days. Currently, 1.8% of the shares of the company are sold short. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Alder Biopharmaceuticals (ALDR), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Nabriva Therapeutics (NBRV), Endo International (ENDP), TG Therapeutics (TGTX), BELLUS Health (BLUSF), Madrigal Pharmaceuticals (MDGL) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Rigel Pharmaceuticals (RIGL).

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.84.

Kindred Biosciences has a market capitalization of $384.65 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]